Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03952312 · ClinicalTrials.gov registry record · NA
Oncotool for Cancer Medications
A NA study, sponsored by Northwestern University.
- Completed
- Registry status
- NA
- Development phase
- 83
- Enrollment target
NCT03952312 is a NA study that has completed, run by Northwestern University. The registered enrollment target is 83 participants.
The verdict
NCT03952312, a NA study, has completed, sponsored by Northwestern University.
- COMPLETED
- Registry status
- NA
- Development phase
- 83 participants
- Enrollment target
Study Summary
The purpose of this study is to examine the efficacy of a psychosocial eHealth intervention on the proposed primary outcomes, TKI adherence and health related quality of life (HRQoL), in patients taking TKIs for cancer management. The intervention components include psychosocial management strategies, cancer medication knowledge and embedded physician reports. The intervention will be delivered via an online application over an 8-week period. Participants in the intervention will complete bi-weekly side effect questionnaires as part of their study involvement, which may trigger an alert to their prescribing physician if they reach a certain threshold. Participants in the control will not complete these questionnaires. Participants are randomized into either an intervention application (described above) or a control application (health information and general health promotion strategies). Aside from having access to the online application for the recommended 8 weeks, participation in this study includes three assessments: baseline (at the beginning of the research study), post-intervention (8 weeks after baseline) and a 6-month follow-up.
Interventions
- BEHAVIORAL Oncotool Intervention (symptom reporting + TKI education)
- BEHAVIORAL Oncotool Control (health information)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 83 participants |
| Start Date | 2020-01-15 |
| Est. Completion | 2022-11-04 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03952312
The ClinicalTrials.gov registry entry for NCT03952312 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 83 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Northwestern University, which has 1,209 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Oncotool Intervention (symptom reporting + TKI education) is the first listed.
NCT03952312 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03952312 about?
NCT03952312 is a clinical study titled "Oncotool for Cancer Medications". The purpose of this study is to examine the efficacy of a psychosocial eHealth intervention on the proposed primary outcomes, TKI adherence and health related quality of life (HRQoL), in patients taking TKIs for cancer management. The intervention components include psychosocial management strategi...
What is the current status of trial NCT03952312?
This trial is currently completed. It is a NA study. The enrollment target is 83 participants. The study started on 2020-01-15. Estimated completion is 2022-11-04.
What interventions are being tested in trial NCT03952312?
The interventions under investigation include: Oncotool Intervention (symptom reporting + TKI education) (BEHAVIORAL), Oncotool Control (health information) (BEHAVIORAL).
Who is sponsoring clinical trial NCT03952312?
This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.